National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital/ Institute of Mental Health), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
Hebei Mental Health Center, Baoding, Hebei Province, China.
Psychiatry Res. 2016 Dec 30;246:303-307. doi: 10.1016/j.psychres.2016.05.063. Epub 2016 Sep 30.
This study was designed to examine the validity and reliability of the Chinese version of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia taking antipsychotics. It was conducted in a sample of 135 patients aged between 18 and 50 years old and diagnosed with schizophrenia. Demographic data and clinical features were assessed with PRSexDQ, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI), and the Udvalg for Kliniske Undersøgelser (UKU) Side Effects Rating Scale. The internal consistency of the Chinese version of PRSexDQ using Cronbach's α was 0.902. The test-retest and inter rater reliability was both high with p<0.001. PRSexDQ was correlated with corresponding items in the UKU Side Effects Rating Scale (Items 4.12-4.16), and showed good sensitivity, specificity, positive and negative predictive value. It could also clearly detect differences in SD rates of three monotherapy groups: patients treated with risperidone had the highest scores, followed by patients treated with olanzapine, whereas patients treated with aripiprazole had the lowest scores. The Chinese version of PRSexDQ is a reliable and valid instrument to assess patients with schizophrenia. Assessed by PRSexDQ, 53.2% of total subjects in our study reported symptoms of SD.
本研究旨在检验中文版精神药物相关性性功能障碍问卷(PRSexDQ-SALSEX)在服用抗精神病药物的精神分裂症患者中的有效性和可靠性。研究对象为 135 名年龄在 18 至 50 岁之间、被诊断为精神分裂症的患者。使用 PRSexDQ、阳性和阴性症状量表(PANSS)、临床总体印象量表(CGI)和 Udvalg for Kliniske Undersøgelser(UKU)副作用评定量表评估人口统计学数据和临床特征。中文版 PRSexDQ 的内部一致性采用 Cronbach's α 检验为 0.902。重测信度和组内信度均较高(p<0.001)。PRSexDQ 与 UKU 副作用评定量表中的相应项目(项目 4.12-4.16)呈高度相关,具有良好的灵敏度、特异性、阳性和阴性预测值。它还可以清楚地检测出三种单药治疗组之间 SD 发生率的差异:利培酮治疗组的评分最高,奥氮平治疗组次之,阿立哌唑治疗组的评分最低。中文版 PRSexDQ 是评估精神分裂症患者的可靠有效的工具。通过 PRSexDQ 评估,我们研究中的 53.2%的受试者报告了性功能障碍的症状。